Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients

References

• Lee S-T, Ji Y, Kim H-J, et al. Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia. Leuk Res. 2012;36(4):418–421. doi:10.1016/j.leukres.2011.12.02122309891
   PubMed Web of Science ®Google Scholar
• Popp HD, Kohl V, Naumann N, et al. DNA damage and DNA damage response in chronic myeloid leukemia. Int J Mol Sci. 2020;21:4.
   Web of Science ®Google Scholar
• Barnes DJ, Palaiologou D, Panousopoulou E, et al. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005;65(19):8912–8919.16204063
   PubMed Web of Science ®Google Scholar
• Cumbo C, Anelli L, Specchia G, Albano F. Monitoring of Minimal Residual Disease (MRD) in chronic myeloid leukemia: recent advances. Cancer Manag Res. 2020;12:3175–3189.32440215
   PubMed Web of Science ®Google Scholar
• Gao S, Hu J, Li Y. Targeting of the Alox12-12-HETE in blast crisis chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Cancer Manag Res. 2020;12:12509–12517.33312001
   PubMed Web of Science ®Google Scholar
• Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol. 2021;113(5):624–631.33782818
   PubMed Web of Science ®Google Scholar
• Skorski T. Genetic mechanisms of chronic myeloid leukemia blastic transformation. Curr Hematol Malig Rep. 2012;7(2):87–93.22328017
   PubMed Web of Science ®Google Scholar
• Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006;20(6):1028–1034.16617318
   PubMed Web of Science ®Google Scholar
• Magistroni V, Mauri M, D’Aliberti D, et al. De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. Haematologica. 2019;104(9):1789–1797.30819912
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Takezako N, Ohashi K, et al. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020;111(3):401–408. doi:10.1007/s12185-019-02801-z31894533
   PubMed Web of Science ®Google Scholar
• Russo D, Garcia-Gutierrez JV, Soverini S, Baccarani M. Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives. J Clin Med. 2020;9:6.
   Web of Science ®Google Scholar
• Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14(1):44.33736651
   PubMed Web of Science ®Google Scholar
• Karbasian Esfahani MM, Evelyn L, Dutcher JP, Wiernik PH. Blastic phase of chronic myelogenous leukemia. Curr Treat Options Oncol. 2006;7(3):189–199.16615875
   PubMedGoogle Scholar
• Zhou L, Shi H, Shi W, et al. Durable molecular remission in a lymphoid BP-CML patient Harboring T315I mutation treated with Anti-CD19 CAR-T therapy. Onco Targets Ther. 2019;12:10989–10995.31997880
   PubMed Web of Science ®Google Scholar
• Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557–560.21274004
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–2264.20592475
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123(22):4391–4402.28743165
   PubMed Web of Science ®Google Scholar
• Gaiger A, Henn T, Hörth E, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86(6):2371–2378.7662984
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–453.17522713
   PubMed Web of Science ®Google Scholar
• Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–4022.14982876
   PubMed Web of Science ®Google Scholar
• Chereda B, Melo JV. Natural course and biology of CML. Ann Hematol. 2015;94(Suppl 2):S107–121.25814077
   PubMed Web of Science ®Google Scholar
• Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol. 2021;113(5):632–641.33772728
   PubMed Web of Science ®Google Scholar
• Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;100825.33773846
   PubMed Web of Science ®Google Scholar
• Yin X, Zhou M, Fu Y, et al. Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade. Cell Signal. 2019;63:109360.31374292
   PubMed Web of Science ®Google Scholar
• Skorski T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma. 2011;52(Suppl 1):23–29.21299457
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 2005;106(6):2128–2137.15914554
   PubMed Web of Science ®Google Scholar
• Radich JP. The biology of chronic myelogenous leukemia progression: who, what, where, and why? Hematol Oncol Clin North Am. 2011;25(5):967–980, v.22054729
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23(18):4100–4109.15867198
   PubMed Web of Science ®Google Scholar
• Bavaro L, Martelli M, Cavo M, Soverini S. Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. Int J Mol Sci. 2019;20:24.
   Web of Science ®Google Scholar
• Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26(16):6082–6093.16880519
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Kurosu T, Kakihana K, Mizuchi D, Miura O. The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. Biochem Biophys Res Commun. 2004;319(4):1272–1275.15194504
   PubMed Web of Science ®Google Scholar
• Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003;101(11):4611–4614.12576318
   PubMed Web of Science ®Google Scholar
• Etienne G, Dulucq S, Huguet F, et al. Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors. Cancer Med. 2019;8(11):5173–5182.31350815
   PubMed Web of Science ®Google Scholar
• Francesco Lanza SB. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells. 1995;13(4):445–452.7549904
   PubMed Web of Science ®Google Scholar
• Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A. 1996;93(23):13137–13142.8917557
   PubMed Web of Science ®Google Scholar
• Liborio Stuppia GC, Peila R, Guanciali-Franchi P, Morizio E, Spadano A, Palka G. p53 loss and point mutations are associated with suppression of apoptosis and progression of CML into myeloid blastic crisis. Cancer Genetic Cytogenetics. 1997;98(1):28–35.
   PubMedGoogle Scholar
• Hiroyuki Nakayama FI, Avitahl N, Sezaki N, et al. Decreases in ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res. 1999;59(16):3931–3934.10463586
   PubMed Web of Science ®Google Scholar
• Albajar M, Gomez-Casares MT, Llorca J, et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res. 2011;9(5):564–576.21460180
   PubMed Web of Science ®Google Scholar
• Gomez-Casares MT, Garcia-Alegria E, Lopez-Jorge CE, et al. MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.). Oncogene. 2013;32(17):2239–2246.22710719
   PubMed Web of Science ®Google Scholar
• Pippa R, Odero MD. The role of MYC and PP2A in the initiation and progression of myeloid leukemias. Cells. 2020;9:3.
   Web of Science ®Google Scholar
• Srutova K, Curik N, Burda P, et al. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. Haematologica. 2018;103(12):2016–2025.30049824
   PubMed Web of Science ®Google Scholar
• Delgado MD, León J. Myc roles in hematopoiesis and leukemia. Genes Cancer. 2010;1(6):605–616.21779460
   PubMedGoogle Scholar
• Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948–961.29967129
   PubMed Web of Science ®Google Scholar
• Adnan Awad S, Dufva O, Ianevski A, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2020.
   Web of Science ®Google Scholar
• Zhao LJ, Wang YY, Li G, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood. 2012;119(12):2873–2882.22318203
   PubMed Web of Science ®Google Scholar
• L-ym S-JZ, Huang Q-H, Guo L, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. pnas. 2007;105(6):2076–2081.
   Web of Science ®Google Scholar
• Adnan Awad S, Dufva O, Ianevski A, et al. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021;35(4):1087–1099.32782381
   PubMed Web of Science ®Google Scholar
• How HR. I treat CML blast crisis. Blood. 2012;120(4):737–747.22653972
   PubMed Web of Science ®Google Scholar
• Chandran RK, Geetha N, Sakthivel KM, et al. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. Gene. 2019;686:85–91.30399426
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351(7):657–667.15306667
   PubMed Web of Science ®Google Scholar
• Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117(24):6660–6668.21490338
   PubMed Web of Science ®Google Scholar
• Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet. 2002;30(1):48–58.11753385
   PubMed Web of Science ®Google Scholar
• Guerzoni C, Bardini M, Mariani SA, et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood. 2006;107(10):4080–4089.16418324
   PubMed Web of Science ®Google Scholar
• Tomasello L, Vezzalini M, Boni C, et al. Regulative loop between β-catenin and protein tyrosine receptor type γ in chronic myeloid leukemia. Int J Mol Sci. 2020;21:7.
   Web of Science ®Google Scholar
• Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198–206.21346257
   PubMed Web of Science ®Google Scholar
• Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760–6768.22039253
   PubMed Web of Science ®Google Scholar
• Chen Z, Shao C, Wang W, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31(3):585–592.27560111
   PubMed Web of Science ®Google Scholar
• Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017;1(26):2541–2552.29296906
   PubMed Web of Science ®Google Scholar
• Braig M, Pallmann N, Preukschas M, et al. A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia. 2014;28(10):2028–2039.24603533
   PubMed Web of Science ®Google Scholar
• Jackie Boultwood SH, Fidler C, Kusec R, et al. Telomere length shortening is associated with disease evolution. Am J Hematol. 1999;61(1):5–9.10331504
   PubMed Web of Science ®Google Scholar
• Drummond M, Lennard A, Brummendorf T, Holyoake T. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. Leuk Lymphoma. 2004;45(9):1775–1781.15223635
   PubMed Web of Science ®Google Scholar
• Tetsuzo Tauchi AN, Sashida G, Takashi Shimamoto JH, Ohyashiki KA, Yamamoto K, Ohyashiki K. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res. 2002;8(11):3341–3347.12429620
   PubMed Web of Science ®Google Scholar
• Heller G, Topakian T, Altenberger C, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016;30(9):1861–1868.27211271
   PubMed Web of Science ®Google Scholar
• Ruggiu M, Oberkampf F, Ghez D, et al. Azacitidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. Leuk Lymphoma. 2018;59(7):1659–1665.29179634
   PubMed Web of Science ®Google Scholar
• Issa JP, Zehnbauer BA, Kaufmann SH, Biel MA, Baylin SB. HIC1 hypermethylation is a late event in hematopoietic neoplasms. Cancer Res. 1997;57(9):1678–1681.9135007
   PubMed Web of Science ®Google Scholar
• Li ZY, Yang L, Liu XJ, Wang XZ, Pan YX, Luo JM. The long noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT pathway in advanced chronic myeloid leukemia. EBioMedicine. 2018;34:61–75.30072211
   PubMed Web of Science ®Google Scholar
• Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukemia in advanced phase. Front Oncol. 2019;9:1132.31709190
   PubMed Web of Science ®Google Scholar
• Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2019;61(3):650–659.31647335
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Shlyakhto V, Lauseker M, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28(10):1988–1992.24798484
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Z, Jiang M, et al. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia. BMC Cancer. 2019;19(1):935.31594548
   PubMed Web of Science ®Google Scholar
• Hughes NSTP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematol Am Soc Hematol Educ Prog. 2018;168–176.
   PubMed Web of Science ®Google Scholar
• Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014;89(6):626–632.24619861
   PubMed Web of Science ®Google Scholar
• Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511–518.24859364
   PubMed Web of Science ®Google Scholar
• Cai Z, Jia X, Zi J, et al. BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia. J Cancer. 2020;11(8):2234–2240.32127950
   PubMed Web of Science ®Google Scholar
• Branford S. Molecular monitoring in chronic myeloid leukemia-how low can you go? Hematol Am Soc Hematol Educ Prog. 2016;2016(1):156–163.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794–3800.12560227
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021;35(5):1229–1242.33833387
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. Ann Hematol. 2000;79(8):424–431.10985361
   PubMed Web of Science ®Google Scholar
• Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood. 2015;125(21):3230–3235.25852053
   PubMed Web of Science ®Google Scholar
• Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191(3):433–441.32352166
   PubMed Web of Science ®Google Scholar
• Nakajima H, Zhao R, Lund TC, et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol. 2002;168(2):643–650.11777957
   PubMed Web of Science ®Google Scholar
• Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102(8):1368–1377.28522576
   PubMed Web of Science ®Google Scholar
• Dong R, Cwynarski K, Entwistle A, et al. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood. 2003;101(9):3560–3567.12506035
   PubMed Web of Science ®Google Scholar
• Inselmann S, Wang Y, Saussele S, et al. Development, function, and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res. 2018;78(21):6223–6234.30166420
   PubMed Web of Science ®Google Scholar
• Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood. 2009;113(19):4681–4689.19252140
   PubMed Web of Science ®Google Scholar
• Kreutzman A, Yadav B, Brummendorf TH, et al. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 2019;8(9):e1638210.31428530
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Khoder A, Hart M, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013;122(2):227–238.23719297
   PubMed Web of Science ®Google Scholar
• Najima Y, Yoshida C, Iriyama N, et al. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res. 2018;66:66–72.29407585
   PubMed Web of Science ®Google Scholar
• Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre Phase 2 trial. Lancet Haematol. 2015;2(12):e528–535.26686407
   PubMed Web of Science ®Google Scholar
• Chen Z, Medeiros LJ, Kantajian HM, et al. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J. 2017;7(2):e521.28157214
   PubMed Web of Science ®Google Scholar
• Cayssials E, Jacomet F, Piccirilli N, et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol. 2019;186(1):54–59.30864168
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Katagiri S, Tauchi T, et al. Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. Br J Haematol. 2012;157(2):254–256.22077498
   PubMed Web of Science ®Google Scholar
• Breccia M, Serrao A, Salaroli A, Loglisci G, Zacheo I, Alimena G. Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. Br J Haematol. 2012;159(5):612–613.23043319
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207–3213.17185463
   PubMed Web of Science ®Google Scholar
• Druker BRIANJ, Sawyers CHARLESL, Kantarjian HAGOP, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engd J Med. 2001;3(345):232.
   Google Scholar
• Perez-Jacobo F, Tuna-Aguilar E, Demichelis-Gomez R, et al. prognostic factors, response to treatment, and survival in patients with chronic myeloid leukemia in blast phase: a single-institution survey. Clin Lymphoma Myeloma Leuk. 2015;15(12):778–784.26500135
   PubMed Web of Science ®Google Scholar
• Jiang H, Xu LP, Liu DH, et al. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant. 2014;49(9):1146–1154.25046218
   PubMed Web of Science ®Google Scholar
• Francisco Cervantes N, Esteve J, Montoto S, Rives S, Rozman C, Montserrat E. ‘Lymphoid’ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol. 1998;100(1):123–128.9450800
   PubMed Web of Science ®Google Scholar
• Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993;94(1):69–74.8420302
   PubMed Web of Science ®Google Scholar
• El Rassi F, Bergsagel JD, Arellano M, et al. Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link? Cancer. 2015;121(6):872–875. doi:10.1002/cncr.2914225387987
   PubMed Web of Science ®Google Scholar
• Bourgne C, Janel A, Berger J, et al. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk348) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML). Leuk Res. 2015;39(3):329–334. doi:10.1016/j.leukres.2014.11.01425612940
   PubMed Web of Science ®Google Scholar
• Lee MY, Park CJ, Cho YU, et al. Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. Cancer Immunol Immunother. 2020;69(11):2223–2232.32474769
   PubMed Web of Science ®Google Scholar